Consensus Palisade Bio, Inc.

Equities

SNCA

US6963894026

Real-time Estimate Cboe BZX Other stock markets 10:57:15 2024-05-10 am EDT			5-day change	1st Jan Change
6.765 ^USD	-2.52%		-13.21%	-24.10%

May. 07	Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	CI
May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT

Evolution of the average Target Price on Palisade Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dde3b1c1fa590d3375929c8.Vv1W_MjymV1M_AbvjOq6SHmekyWL9IFvi8mDYnLKaWI.IpI_mq-I3ip1vmmuvZ38eDfQolHEreooyf35FDmFHixljWeK_7nXa3ySSw~9a87c10f451fc45b0536ff2891bad222

Analyst Recommendations on Palisade Bio, Inc.

Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	Nov. 17	MT
Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	23-05-16	MT
Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $5	23-03-30	MT
Ladenburg Lowers Palisade Bio's Price Target to $1.50 From $5, Maintains Buy Rating	22-08-23	MT
Maxim Group Downgrades Palisade Bio to Hold From Buy	22-08-19	MT
Ladenburg Thalmann Starts Palisade Bio at Buy With $5 Price Target	22-02-02	MT
PALISADE BIO : Maxim Starts Palisade Bio at Buy With $7 Price Target	21-08-31	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.94 USD

Average target price

33.75 USD

Spread / Average Target

+386.31%

High Price Target

45 USD

Spread / Highest target

+548.41%

Low Price Target

22.5 USD

Spread / Lowest Target

+224.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Palisade Bio, Inc.

Maxim
Ladenburg Thalmann

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar